Jan 10,2017

Dexcom G5® Mobile Continuous Glucose Monitoring (CGM) System Now Compatible on Android Smart Phones and Watches in Europe

DexCom, Inc. (NASDAQ:DXCM), the leader in Continuous Glucose Monitoring (CGM) for patients with diabetes, announced today that its G5 Mobile CGM System is now compatible on Android smart devices throughout Europe and South Africa. This new platform will be launching into select European countries today and continue throughout the fourth quarter of 2017.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 11,2017

BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call

BD(Becton, Dickinson and Company)(NYSE:BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2017 earnings conference call on Thursday, February 2, 2017, at 8:00 a.m. (ET).

View Analyst & Ambassador Comments
Go to original news
Jan 23,2017

Dexcom Launches Dexcom CLARITY® Diabetes Management Solution in EMEA

Dexcom announced the general availability of the Dexcom CLARITY diabetes management solution in EMEA, enhancing user data visibility and analysis. Dexcom CLARITY works with the Dexcom CGM System by automatically sending a patient's CGM data to a secure cloud-based system that can easily be accessed by the patient's health care professional. The software platform allows for automated summaries and reports for physicians, empowering them to help their patients better manage their diabetes.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 23,2017

Insulet Corporation to Announce Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year 2016 on February 27, 2017 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Jan 31,2017

INDUSTRY LEADERS ASCENSIA DIABETES CARE AND GLOOKO ANNOUNCE DIABETES TECHNOLOGY PARTNERSHIP TO DELIVER INTEGRATED DIABETES DATA SOLUTIONS

Ascensia Diabetes Care and Glooko, Inc today announced a global technology partnership designed to bring together their state-of-the-art diabetes management solutions, and improve diabetes data management and analytics. This collaboration includes integration of Glooko's Diabetes Data Management Platform and Ascensia's CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose monitoring systems. The integration of these solutions will allow blood glucose data to be accessed by Glooko's Mobile App and Clinic Data Upload products directly from the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE meters via Bluetooth® connectivity and through an automatic feed via the CONTOUR CLOUD.

COLLABORATION PARTNERSHIP

#connected device

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 10,2017

Sano Intelligence is working on a wearable continuous glucose monitor in the form of an adhesive patch and companion app

Sano Intelligence is working on a wearable continuous glucose monitor in the form of an adhesive patch and companion app – but it won't be marketed, at least initially, to people with diabetes. Sano shared new details about their device with Gizmodo, who cast some doubt on the wisdom of a CGM for wellness. The company is marketing the device as a product for “metabolic insight” for people who do not have diabetes, thereby dodging the purview of the FDA. Sano wants to get the device into beta release this year, and claims it would offer the everyday person data that would provide “personalized metabolic insights in real-time” to help them figure out how what they eat affects their blood sugar and metabolism.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 12,2017

Apple's 12 picks for diabetes management apps, 2017 edition

Read on for Apple’s current 12 picks for apps for managing diabetes: One Drop, OneTouch Reveal, Dexcom G5 Mobile, Blip Notes, mySugr, Dexcom Follow and more.

View Analyst & Ambassador Comments
Go to original news
Feb 15,2017

Real-world data shows Abbott Freestyle users scan often, and that correlates with lower HbA1Cs

The real world data, mostly of European users, spans two years and includes data from 50,000 readers and 285,000 sensors . It represents 86.4 million monitoring hours and 63.8 million distinct scans. What Abbott found was that users of the FreeStyle Libre system scan about 16 times per day on average. But even more interesting for the company are the other health benefits that correlate with increased scanning. Although they aren't able to prove causation, Abbott saw that there was a strong correlation between number of scans per day, time below 55 mg/dL, and estimated A1C.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 16,2017

Livongo, Voluntis team up to offer integrated app for diabetes management program

Chronic disease management company Livongo is collaborating with Voluntis, the Paris, France-based company that develops companion apps for medical devices, to offer an integrated program, insulin delivery system and app for people with type 2 diabetes. Members will have access to the Livongo for Diabetes Program with Voluntis’ Insulia.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 17,2017

Roundup: News from the Advanced Technologies & Treatments for Diabetes

Nonprofit organization T1D Exchange published a major study in Diabetes Care yesterday (and presented the research at the conference). The data re-affirms the FDA's recent clearance of Dexcom's CGM for insulin dosing. The study looked at 226 adult CGM users for six months. Of those, 149 dosed their insulin using the CGM and 77 used a fingerstick glucometer in addition, as is currently required for most CGMs. There was no difference in outcomes between the two groups.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES